Lomecel-B (laromestrocel) / Longeveron 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lomecel-B (laromestrocel) / Longeveron
CLEARMIND, NCT05233774: Lomecel-B Effects on Alzheimer's Disease

Completed
2
50
US
Allogeneic MSC, Placebo
Longeveron Inc., bioRASI, LLC
Mild Alzheimer's Disease
09/23
09/23
SIRONA, NCT02587572: Safety and Efficacy Trial Using Allogeneic Human Mesenchymal Stem Cells: The Trial

Withdrawn
2
40
NA
Peripheral Intravenous (IV) infusion of LMSCs, LMSCs, Biological
Longeveron Inc.
Metabolic Disease, Endothelial Dysfunction
12/23
12/23
ELPISII, NCT04925024: Evaluation of Lomecel-B™ Injection in Patients With Hypoplastic Left Heart Syndrome (HLHS): A Phase IIb Clinical Trial.

Recruiting
2
38
US
Lomecel-B medicinal signaling cells
Longeveron Inc., National Heart, Lung, and Blood Institute (NHLBI), Ann & Robert H Lurie Children's Hospital of Chicago, The University of Texas Health Science Center, Houston
Hypoplastic Left Heart Syndrome
06/25
08/25
ELPIS, NCT03525418: Lomecel-B Delivered During Stage II Surgery for Hypoplastic Left Heart Syndrome

Active, not recruiting
1/2
10
US
Longeveron Mesenchymal Stem Cells, LMSCs
Longeveron Inc.
HLHS
06/24
12/25
RECOVER, NCT04629105: Regenerative Medicine for COVID-19 and Flu-Elicited ARDS Using Lomecel-B

Active, not recruiting
1
70
US
Longeveron Mesenchymal Stem Cells (LMSCs), Placebo
Longeveron Inc.
ARDS, Human, Covid19
06/24
07/25

Download Options